Carcinoid Tumors Presenting as Appendicitis Abstract #1274

Introduction: Many conditions related to appendix present as appendicitis. These conditions can range from fecolith obstruction to tumors .Carcinoid tumors are most common tumors to present in appendix. Most of the carcinoid tumors in appendix present as appendicitis. Majority of the cases are diagnosed after histopathological examination. Tumors with the size of 2cm are treated with right hemicolectomy.
Aim(s): To determine the frequency of carcinoid tumors in appendectomies using histopathological data.
Materials and methods: A retrospective study was conducted at Sir Ganga Ram Hospital, Lahore for a time period of 7 years from June 2005 to November 2012. 2,231 appendectomies were analyzed, out of which 13 appendectomy specimens were diagnosed as carcinoid tumors. Incidental and negative appendectomies were excluded from this study.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Arooj Fatima
Authors: Fatima A

To read results and conclusion, please login ...

Further abstracts you may be interested in

#70 The validity of Ki-67 as a prognostic indicator in patients with appendiceal carcinoid tumor
Introduction: Carcinoid tumors of the appendix are rare and often discovered incidentally through appendectomy. Most are clinically benign but may be associated with metastatic disease. Ki-67, a nuclear protein structurally associated with chromatin, is an excellent marker for measuring cell proliferation and it has been shown to correlate with the outcome in pancreatic and ileocecal carcinoids.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Eric Y Liu
Authors: Liu E, Telem D A, Hwang J, Warner R R P, ...
#139 Association of carcinoid with noncarcinoid neoplasms
Introduction: Carcinoid tumors have a complex disease spectrum. Most have a benign clinical course, but some are aggressive, with invasive growth, metastasis and short survival. In carcinoid tumors, more than 20% are associated with noncarcinoid neoplasms. When the second tumor is a more malignant lesion, the prognosis usually is correlated more closely with the noncarcinoid malignant neoplasm.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Joao C Ribeiro
#308 Goblet Cell Carcinoid Tumors - A Retrospective Study of Clinical Presentation and Survival
Introduction: Goblet cell carcinoids (GCC) are rare mixed tumors, with partial neuroendocrine differentiation and intestinal-type goblet cell morphology. They usually have a highly malignant potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Henning Grønbæk
Authors: Holt N, Villadsen G, Krogh K, Olesen R, ...
#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero